601
Participants
Start Date
April 30, 2016
Primary Completion Date
July 31, 2017
Study Completion Date
July 31, 2017
GSP 301 NS
FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
GSP 301 Placebo NS pH 3.7
2 spray in each nostril twice daily for 52 weeks
GSP 301 Placebo NS pH 7.0
2 spray in each nostril twice daily for 52 weeks
Investigational Site 2, Hot Springs
Investigational Site 28, Encinitas
Investigational Site 27, San Diego
Investigational Site 29, San Diego
Investigational Site 32, Denver
Investigational Site 26, Aventura
Investigational Site 9, Miami
Investigational Site 33, Tallahassee
Investigational Site 11, Stockbridge
Investigational Site 4, Louisville
Investigational Site 5, Bethesda
Investigational Site 15, St Louis
Investigational Site 30, Bellevue
Investigational Site 19, Skillman
Investigational Site 18, Corning
Investigational Site 7, High Point
Investigational Site 21, Raleigh
Investigational Site 16, Sylvania
Investigational Site 22, Pittsburgh
Investigational Site 13, Spartanburg
Investigational Site 23, Austin
Investigational Site 24, Austin
Investigational Site 3, Austin
Investigational Site 31, Dallas
Investigational Site 34, El Paso
Investigational Site 6, Kerrville
Investigational Site 14, New Braunfels
Investigational Site 10, San Antonio
Investigational Site 12, San Antonio
Investigational Site 17, San Antonio
Investigational Site 1, San Antonio
Investigational Site 20, San Antonio
Investigational Site 25, Waco
Investigational Site 8, Waco
Glenmark Specialty S.A.
INDUSTRY